RxDoctor Payments Data

Scott Westhouse, DO

Ophthalmology · Grand Rapids, MINPI 1306016977

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $103,288 of the $137,553 with a category attached, or 75.1%. Regeneron Healthcare Solutions, Inc. accounts for 80.2% of it on its own, with 26 other manufacturers making up the rest. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$137,553in general payments, 2019–2025

Across 312 payments — averaging $440.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$110K
  • Alimera Sciences, Inc.$7K
  • Genentech USA, Inc.$6K
  • Novartis$4K
  • Apellis Pharmaceuticals, Inc.$4K
  • US Retina LLC$2K
  • plus $3K from 21 others
$387,176in research payments, 2019–2025

Across 96 payments — averaging $4033.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$373K
  • Regeneron$9K
  • Roche TCRC, Inc.$5K

What the payments were for

  • Consulting fees$10,8258%
  • Speaking & faculty fees$103,28875%
  • Travel & lodging$4,8804%
  • Food & beverage$16,20812%
  • Ownership interest$2,3522%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,553 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$1,181,194
Medicare patients
492
Services billed
8,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate223$7,941
Difluprednate41$5,283
SimbrinzaBrinzolamide/Brimonidine Tart18$3,460
Bromfenac Sodium26$2,980
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat45$1,004
ValacyclovirValacyclovir Hcl17$961
Timolol Maleate85$954
Brimonidine Tartrate46$697
Acetazolamide14$505
Dorzolamide Hcl27$490
Latanoprost28$453
Gentamicin Sulfate77$450
Prednisone27$102

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →